Biotie Therapies - Company Announcement

ACORDA HAS FILED THE DRAFT TENDER OFFER DOCUMENT RELATING TO ITS PUBLIC TENDER OFFER FOR BIOTIE THERAPIES WITH THE FINNISH FINANCIAL SUPERVISORY AUTHORITY

BIOTIE THERAPIES CORP.         STOCK  EXCHANGE  RELEASE    3 March 2016, 9.00
a.m.



ACORDA HAS FILED THE DRAFT TENDER OFFER DOCUMENT RELATING TO ITS PUBLIC TENDER
OFFER FOR BIOTIE THERAPIES WITH THE FINNISH FINANCIAL SUPERVISORY AUTHORITY

Biotie Therapies Corp. ("Biotie" or the "Company") announced on 19 January 2016
that the Company and Acorda Therapeutics, Inc. ("Acorda") had entered into a
combination agreement whereby Acorda will make a public tender offer to purchase
all of the issued and outstanding shares, American Depositary Shares, stock
options, share units and warrants in Biotie that are not owned by Biotie or any
of its subsidiaries (the "Tender Offer").

Biotie has been informed by Acorda that the draft tender offer document to be
released in connection with the Tender Offer has been filed for approval with
the Finnish Financial Supervisory Authority ("FIN-FSA"). Acorda will commence
the offer period under the Tender Offer as soon as practicable after the receipt
of both the FIN-FSA approval of the tender offer document and certain regulatory
relief from the US Securities and Exchange Commission ("SEC"). Currently, the
offer period is expected to commence by mid-March 2016.


Turku, March 3, 2016

Biotie Therapies Corp.
Timo Veromaa
President and CEO

For further information, please contact:
Virve Nurmi, Biotie Therapies Corp.
tel. +358 2 274 8900, e-mail: virve.nurmi@biotie.com

DISTRIBUTION:
www.biotie.com
Nasdaq Helsinki Ltd
Main Media

INFORMATION REGARDING BIOTIE

Biotie  is  a  specialized  drug  development  company  focused  on products for
neurodegenerative  and psychiatric disorders. Biotie's development has delivered
Selincro  (nalmefene) for alcohol dependence,  which received European marketing
authorization  in 2013 and is currently being  marketed across Europe by partner
Lundbeck.  The current  development products  include tozadenant for Parkinson's
disease, which is in Phase 3 development, and two additional compounds which are
in  Phase 2 development  for cognitive  disorders including  Parkinson's disease
dementia,  and primary sclerosing cholangitis (PSC),  a rare fibrotic disease of
the liver.

INFORMATION REGARDING ACORDA

Founded  in  1995, Acorda  is  a  biotechnology  company  focused  on developing
therapies that improve the lives of people with neurological disorders, with its
common stock listed on Nasdaq US.

Acorda  has  an  industry  leading  pipeline  of  novel  neurological  therapies
addressing  a  range  of  disorders,  including  multiple sclerosis, Parkinson's
disease,  post-stroke walking  deficits, epilepsy  and migraine.  Acorda markets
three  FDA-approved therapies, including AMPYRA (dalfampridine) Extended Release
Tablets, 10 mg.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

SOME OF THE STATEMENTS CONTAINED IN THIS ANNOUNCEMENT ARE FORWARD-LOOKING
STATEMENTS, INCLUDING STATEMENTS REGARDING THE EXPECTED CONSUMMATION OF THE
ACQUISITION, WHICH INVOLVES A NUMBER OF RISKS AND UNCERTAINTIES, INCLUDING THE
SATISFACTION OF CLOSING CONDITIONS FOR THE ACQUISITION, SUCH AS REGULATORY
APPROVAL FOR THE TRANSACTION AND THE TENDER OF AT LEAST 90% OF THE OUTSTANDING
SHARES AND VOTING RIGHTS OF THE COMPANY, THE POSSIBILITY THAT THE TRANSACTION
WILL NOT BE COMPLETED AND OTHER RISKS AND UNCERTAINTIES DISCUSSED IN THE
COMPANY'S PUBLIC FILINGS WITH THE SEC, INCLUDING THE "RISK FACTORS" SECTION OF
THE COMPANY'S REGISTRATION STATEMENT ON FORM F-1 (NO. 333-204147), AS WELL AS
THE TENDER OFFER DOCUMENTS TO BE FILED BY ACORDA AND THE
SOLICITATION/RECOMMENDATION STATEMENT TO BE FILED BY THE COMPANY. THESE
STATEMENTS ARE BASED ON CURRENT EXPECTATIONS, ASSUMPTIONS, ESTIMATES AND
PROJECTIONS, AND INVOLVE KNOWN AND UNKNOWN RISKS, UNCERTAINTIES AND OTHER
FACTORS THAT MAY CAUSE RESULTS, LEVELS OF ACTIVITY, PERFORMANCE OR ACHIEVEMENTS
TO BE MATERIALLY DIFFERENT FROM ANY FUTURE STATEMENTS. THESE STATEMENTS ARE
GENERALLY IDENTIFIED BY WORDS OR PHRASES SUCH AS "BELIEVE", "ANTICIPATE",
"EXPECT", "INTEND", "PLAN", "WILL", "MAY", "SHOULD", "ESTIMATE", "PREDICT",
"POTENTIAL", "CONTINUE" OR THE NEGATIVE OF SUCH TERMS OR OTHER SIMILAR
EXPRESSIONS. IF UNDERLYING ASSUMPTIONS PROVE INACCURATE OR UNKNOWN RISKS OR
UNCERTAINTIES MATERIALIZE, ACTUAL RESULTS AND THE TIMING OF EVENTS MAY DIFFER
MATERIALLY FROM THE EXPECTED RESULTS AND/OR TIMING DISCUSSED IN THE FORWARD-
LOOKING STATEMENTS, AND YOU SHOULD NOT PLACE UNDUE RELIANCE ON THESE
STATEMENTS.  ACORDA AND THE COMPANY DISCLAIM ANY INTENT OR OBLIGATION TO UPDATE
ANY FORWARD-LOOKING STATEMENTS AS A RESULT OF DEVELOPMENTS OCCURRING AFTER THE
PERIOD COVERED BY THIS ANNOUNCEMENT OR OTHERWISE.

ADDITIONAL INFORMATION AND WHERE TO FIND IT

THE TENDER OFFER FOR THE OUTSTANDING SHARES, AMERICAN DEPOSITARY SHARES,
WARRANTS AND OTHER OUTSTANDING EQUITY INSTRUMENTS IN THE COMPANY (THE "OFFER")
HAS NOT BEEN COMMENCED. THIS ANNOUNCEMENT IS FOR INFORMATIONAL PURPOSES ONLY AND
DOES NOT CONSTITUTE AN OFFER TO PURCHASE OR A SOLICITATION OF AN OFFER TO SELL
COMPANY SECURITIES. THE SOLICITATION AND OFFER TO BUY COMPANY SECURITIES WILL
ONLY BE MADE PURSUANT TO AN OFFER TO PURCHASE AND RELATED MATERIALS.  AT THE
TIME THE OFFER IS COMMENCED, ACORDA WILL FILE A TENDER OFFER STATEMENT ON
SCHEDULE TO WITH THE SEC AND THEREAFTER, THE COMPANY WILL FILE A
SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 WITH RESPECT TO THE
OFFER. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THESE MATERIALS
CAREFULLY WHEN THEY BECOME AVAILABLE SINCE THEY WILL CONTAIN IMPORTANT
INFORMATION, INCLUDING THE TERMS AND CONDITIONS OF THE OFFER.  THE OFFER TO
PURCHASE, SOLICITATION/RECOMMENDATION STATEMENT AND RELATED MATERIALS WILL BE
FILED BY ACORDA AND THE COMPANY WITH THE SEC, AND INVESTORS AND SECURITY HOLDERS
MAY OBTAIN A FREE COPY OF THESE MATERIALS (WHEN AVAILABLE) AND OTHER DOCUMENTS
FILED BY ACORDA AND THE COMPANY WITH THE SEC AT THE WEBSITE MAINTAINED BY THE
SEC AT WWW.SEC.GOV. INVESTORS AND SECURITY HOLDERS MAY ALSO OBTAIN FREE COPIES
OF THE SOLICITATION/RECOMMENDATION STATEMENT AND OTHER DOCUMENTS FILED WITH THE
SEC BY THE COMPANY AT WWW.BIOTIE.COM.


[HUG#1991470]